Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for a study evaluating BinD19 treatment in relapsed/refractory B-cell ALL and B-cell lymphoma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Lymphoma

Drugs mentioned

• BinD19

Snippet

Sponsor: Shenzhen BinDeBio Ltd. | Conditions: Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN